Retour
Prix Redhill Biopharma Ltd (RDHL)
Graphique du cours de l'action RDHL
RDHL Gagner
Redhill Biopharma Ltd
$1.36
3.81%
$0.05
À la fermeture : Jan 16, 16:00:00 GMT-5
$1.35
-0.02%
$0
Post-Marché: Jan 16, 20:00:00 GMT-5
Statistiques clés
Clôture préc.
$1.31
Prix d'ouverture
$1.33
Plage de la journée
$1.26 - $1.39
Plage de 52 semaines
$0.905 - $6.8
Volume
86.7K
Volume moyen
1.3M
BPA (TTM)
-0.00
Rendement en dividend
--
Capitalisation boursière
$4.5M
Qu’est-ce que RDHL ?
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved